亚胺培南联合磷霉素作为脊柱骨髓炎的挽救治疗
Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis.
作者信息
Nakamura Itaru, Yamaguchi Tetsuo, Aoki Kotaro, Miura Yuri, Sato Satoko, Fujita Hiroaki, Watanabe Hidehiro
机构信息
Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.
Department of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University, Tokyo, Japan
出版信息
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01746-20.
Abstract
We applied combination antibiotic therapy to treat vertebral osteomyelitis and a psoas abscess caused by glycopeptide-intermediate (MIC, 2 μg/ml) and daptomycin-nonsusceptible (>2 μg/ml) methicillin-resistant The Etest synergy test showed the largest synergistic effects for imipenem/cilastatin and fosfomycin. Whole-gene sequencing showed amino acid changes in SA0802, SA1193 (), and SA1531 (). Four weeks of combination treatment using imipenem/cilastatin (1.5 g per day) and fosfomycin (4.0 g per day) resulted in clinical improvement.
摘要
我们应用联合抗生素疗法治疗由糖肽中介（最低抑菌浓度，2μg/ml）和对达托霉素不敏感（>2μg/ml）的耐甲氧西林金黄色葡萄球菌引起的椎体骨髓炎及腰大肌脓肿。Etest协同试验显示亚胺培南/西司他丁和磷霉素具有最大的协同效应。全基因测序显示SA0802、SA1193（）和SA1531（）存在氨基酸变化。使用亚胺培南/西司他丁（每日1.5g）和磷霉素（每日4.0g）进行四周的联合治疗使病情得到临床改善。
相似文献
1
Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01746-20.
2
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Infection: a Novel Combination Therapy.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.02039-20.
3
Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial.
Clin Infect Dis. 2014 Oct 15;59(8):1105-12. doi: 10.1093/cid/ciu580. Epub 2014 Jul 21.
4
Vertebral osteomyelitis caused by vancomycin-tolerant methicillin-resistant Staphylococcus aureus bacteremia: Experience with teicoplanin plus fosfomycin combination therapy.
J Microbiol Immunol Infect. 2016 Aug;49(4):600-3. doi: 10.1016/j.jmii.2013.09.002. Epub 2013 Nov 21.
5
[Effectiveness and safety of fosfomycin plus imipenem as rescue therapy for bacteremia andendocarditis due to methicillin-resistant Staphylococcus aureus: a multi-center clinical trial ].
Med Mal Infect. 2015 Jan-Feb;45(1-2):63-4. doi: 10.1016/j.medmal.2014.10.009.
6
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Feb;55(2):931-3. doi: 10.1128/AAC.00881-10. Epub 2010 Nov 22.
7
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Antimicrob Agents Chemother. 2011 Nov;55(11):4999-5003. doi: 10.1128/AAC.00584-11. Epub 2011 Aug 22.
8
Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2013 Jan;57(1):606-10. doi: 10.1128/AAC.01570-12. Epub 2012 Oct 22.
9
Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.
Antimicrob Agents Chemother. 2015 Feb;59(2):859-63. doi: 10.1128/AAC.04246-14. Epub 2014 Nov 17.
10
Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):478-86. doi: 10.1128/AAC.02139-15. Print 2016 Jan.
引用本文的文献
1
Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.
Microorganisms. 2025 Apr 23;13(5):963. doi: 10.3390/microorganisms13050963.
2
Multidisciplinary Management of Sternal Osteomyelitis Due to after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature.
Microorganisms. 2023 Nov 3;11(11):2699. doi: 10.3390/microorganisms11112699.
3
Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Meningitis and Bacteremia.
Infect Dis Rep. 2021 Sep 8;13(3):843-854. doi: 10.3390/idr13030076.
4
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Infection: a Novel Combination Therapy.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.02039-20.
本文引用的文献
1
Left ventricular assist device-associated endocarditis involving multiple clones of Staphylococcus aureus with distinct antimicrobial susceptibility patterns.
Int J Infect Dis. 2019 Jul;84:44-47. doi: 10.1016/j.ijid.2019.05.001. Epub 2019 May 7.
2
Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin.
Antimicrob Agents Chemother. 2015 Aug;59(8):5092-3. doi: 10.1128/AAC.00746-15. Epub 2015 Jun 1.
3
Evolution and single-nucleotide polymorphisms in methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to vancomycin and daptomycin, based on determination of the complete genome.
Antimicrob Agents Chemother. 2015;59(6):3585-7. doi: 10.1128/AAC.05159-14. Epub 2015 Mar 16.
4
First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin.
BMC Infect Dis. 2014 Aug 23;14:459. doi: 10.1186/1471-2334-14-459.
5
Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.
J Antimicrob Chemother. 2014 Feb;69(2):568-71. doi: 10.1093/jac/dkt396. Epub 2013 Oct 9.
6
Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.
PLoS One. 2013 Aug 19;8(8):e71151. doi: 10.1371/journal.pone.0071151. eCollection 2013.
7
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4.
8
Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.
Clin Infect Dis. 2005 Aug 15;41(4):507-14. doi: 10.1086/431979. Epub 2005 Jul 6.
9
In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2005 Jul;49(7):2959-64. doi: 10.1128/AAC.49.7.2959-2964.2005.
10
Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Arch Intern Med. 2002 Oct 28;162(19):2229-35. doi: 10.1001/archinte.162.19.2229.
Zotero 插件